Condition: Solid Tumor · Advanced Solid Tumor · Metastatic Solid Tumor · Sponsor: Exelixis
This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE\[s\]); and the dose expansion stage is to evaluate the preliminary antitumor activity of XB628 as a single agent and in combination with zanzalintinib.
This description comes directly from the study's public registry record.
Exelixis Clinical Trials · 1-888-EXELIXIS (888-393-5494) · druginfo@exelixis.com
Backup or International · 650-837-7400
Always discuss trial participation with your own doctor first.
| Exelixis Clinical Site #5 | San Francisco, California, United States | Recruiting |
| Exelixis Clinical Site #4 | New Haven, Connecticut, United States | Recruiting |
| Exelixis Clinical Site #8 | Tampa, Florida, United States | Recruiting |
| Exelixis Clinical Site #10 | Boston, Massachusetts, United States | Recruiting |
| Exelixis Clinical Site #11 | Boston, Massachusetts, United States | Recruiting |
| Exelixis Clinical Site #6 | St Louis, Missouri, United States | Recruiting |
| Exelixis Clinical Site #7 | New York, New York, United States | Recruiting |
| Exelixis Clinical Site #1 | Hickory, North Carolina, United States | Recruiting |
| Exelixis Clinical Site #3 | Nashville, Tennessee, United States | Recruiting |
| Exelixis Clinical Site #9 | Houston, Texas, United States | Recruiting |
| Exelixis Clinical Site #2 | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06952010